Telitacicept treatment in IgA nephropathy: A retrospective study
Abstract
Objectives Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease and is the leading causes of chronic kidney disease (CKD). New therapies are urging in this area. The effectiveness and safety of telitacicept, a new potential drug targeting B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), in real-world management of IgA nephropathy requires further investigation. This study was designed to evaluate the efficacy and safety of telitacicept in patients with IgA nephropathy from our center. Methods This retrospective analysis included 21 primary IgAN patients receiving telitacicept. Baseline characteristics and follow-up data were collected. We assessed changes in proteinuria, complete remission rates, change of eGFR. Adverse events occurred during the treatment were collected. Results Telitacicept treatment resulted in substantial proteinuria reduction (76% decrease from 1.67 to 0.4 g/24h, p<0.001), with 29% achieving complete remission. Renal function remained stable throughout follow-up. Notably, some patients with advanced kidney disease (eGFR <30 mL/min/1.73m 2 ) showed preserved renal function. Safety monitoring revealed minor adverse events without treatment discontinuations. Combined therapy also revealed a satisfied efficacy and safety. Conclusion Telitacicept demonstrates robust proteinuria reduction and renal function preservation in real-world IgAN treatment, while maintaining a favorable safety profile even in advanced disease stages.
Related
- Preliminary evaluation of the efficacy and safety of telitacicept in children with IgA nephropathy
- Combined and simultaneous use of Nefecon and irbesartan in treatment-naïve primary IgA nephropathy : A retrospective study
- Efficacy and safety of low-dose telitacicept in IgA nephropathy: a real-world study.
- Telitacicept for the treatment of Sjögren’s disease complicated by unilateral vocal fold immobility, severe hypergammaglobulinemia, and diabetes: a case report
- Treatment and practical considerations of IgA nephropathy.
BibTeX
@article{qin2026telitacicept,
title = {{Telitacicept treatment in IgA nephropathy: A retrospective study}},
author = {Huazhang Qin and Hanyong Liu and Ya Li and Qiu Jin and Yisha Huang and Zhen Wang and Liping Sun and Nan Hu and Hualin Ma and Xinzhou Zhang},
journal = {SAGE Open Medicine},
year = {2026},
month = nov,
doi = {10.1177/20503121261504783},
url = {https://doi.org/10.1177/20503121261504783},
note = {CC BY},
}
RIS
TY - JOUR
TI - Telitacicept treatment in IgA nephropathy: A retrospective study
AU - Huazhang Qin
AU - Hanyong Liu
AU - Ya Li
AU - Qiu Jin
AU - Yisha Huang
AU - Zhen Wang
AU - Liping Sun
AU - Nan Hu
AU - Hualin Ma
AU - Xinzhou Zhang
PY - 2026
DA - 2026/11/05
JO - SAGE Open Medicine
DO - 10.1177/20503121261504783
UR - https://doi.org/10.1177/20503121261504783
AB - Objectives Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease and is the leading causes of chronic kidney disease (CKD). New therapies are urging in this area. The effectiveness and safety of telitacicept, a new potential drug targeting B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), in real-world management of IgA nephropathy requires further investigation. This study was designed to evaluate the efficacy and safety of telitacicept in patients with IgA nephropathy from our center. Methods This retrospective analysis included 21 primary IgAN patients receiving telitacicept. Baseline characteristics and follow-up data were collected. We assessed changes in proteinuria, complete remission rates, change of eGFR. Adverse events occurred during the treatment were collected. Results Telitacicept treatment resulted in substantial proteinuria reduction (76% decrease from 1.67 to 0.4 g/24h, p<0.001), with 29% achieving complete remission. Renal function remained stable throughout follow-up. Notably, some patients with advanced kidney disease (eGFR <30 mL/min/1.73m 2 ) showed preserved renal function. Safety monitoring revealed minor adverse events without treatment discontinuations. Combined therapy also revealed a satisfied efficacy and safety. Conclusion Telitacicept demonstrates robust proteinuria reduction and renal function preservation in real-world IgAN treatment, while maintaining a favorable safety profile even in advanced disease stages.
SN - 2050-3121
ER -